Meeting
2017 ASCO Annual Meeting
Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).
Authors
Frederick Lundry Locke
H. Lee Moffitt Cancer Canter and Research Institute, Tampa, FL
Frederick Lundry Locke , Sattva Swarup Neelapu , Nancy L. Bartlett , Lazaros J. Lekakis , David Bernard Miklos , Caron Alyce Jacobson , Ira Braunschweig , Olalekan O. Oluwole , Tanya Siddiqi , Yi Lin , John Timmerman , Patrick Michael Reagan , Adrian Bot , John Rossi , Lynn Navale , Yizhou Jiang , Jeff Aycock , Meg Elias , Jeffrey S. Wiezorek , William Y. Go
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT02348216
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7512)
DOI
10.1200/JCO.2017.35.15_suppl.7512
Abstract #
7512
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
First Author: Paolo Strati
Poster
2019 ASCO Annual Meeting
Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL).
First Author: Sattva Swarup Neelapu
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2018 ASCO Annual Meeting
Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
First Author: Frederick Lundry Locke